Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Update

Daré Bioscience, Inc. (NASDAQ:DARE) saw a significant increase in short interest in May. As of May 31st, there was short interest totalling 600,200 shares, an increase of 12.6% from the May 15th total of 532,900 shares. Based on an average daily trading volume, of 675,100 shares, the short-interest ratio is currently 0.9 days.

Institutional Investors Weigh In On Daré Bioscience

A hedge fund recently bought a new stake in Daré Bioscience stock. Armistice Capital LLC purchased a new position in Daré Bioscience, Inc. (NASDAQ:DARE) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 6,470,000 shares of the biotechnology company’s stock, valued at approximately $2,988,000. Armistice Capital LLC owned about 7.37% of Daré Bioscience at the end of the most recent reporting period. Institutional investors and hedge funds own 6.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on DARE shares. Brookline Capital Management raised Daré Bioscience from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research report on Wednesday, May 15th. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Daré Bioscience in a research report on Wednesday, May 15th.

Daré Bioscience Stock Performance

Shares of Daré Bioscience stock traded up $0.01 during trading on Friday, hitting $0.45. The company’s stock had a trading volume of 229,619 shares, compared to its average volume of 538,052. Daré Bioscience has a 52 week low of $0.27 and a 52 week high of $0.98. The company has a market capitalization of $45.47 million, a PE ratio of -1.41 and a beta of 1.35. The company has a fifty day simple moving average of $0.39 and a two-hundred day simple moving average of $0.39.

Daré Bioscience (NASDAQ:DARE) last announced its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.52 million. During the same period last year, the company earned ($0.09) earnings per share. As a group, analysts predict that Daré Bioscience will post -0.23 EPS for the current year.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.